Aquinox: AQX-1125 Fails To Show Efficacy In COPD With Frequent Exacerbations

(RTTNews) - Aquinox Pharmaceuticals Inc (AQXP), a clinical-stage pharmaceutical company, on Thursday said its Phase 2 FLAGSHIP clinical trial failed to demonstrate efficacy in chronic obstructive pulmonary disease ("COPD") patients with a history of frequent exacerbations.

In the FLAGSHIP trial, patients treated with 200 mg oral, once daily AQX-1125 for 12 weeks demonstrated no difference in COPD symptoms compared to placebo, as measured by EXACT, a patient-reported outcome tool.

Consistent with past results, the FLAGSHIP trial demonstrated AQX-1125 to be well tolerated. The overall adverse event rate was similar between AQX-1125 and placebo.

"We believe that FLAGSHIP was a robust and well conducted trial and the results are conclusive," said David Main, CEO at Aquinox. "Given the encouraging activity seen in our recent LEADERSHIP trial our focus will be on the further development of AQX-1125 in bladder pain syndrome/interstitial cystitis. In addition, we are awaiting results from our KINSHIP trial in atopic dermatitis."